Aurora Cannabis Inc., (NASDAQ: ACB), reported a return of profitability in its first quarter fiscal year, driven by its medical cannabis division.
Following the announcement, shares of the licensed cannabis producers surged by 11%.
Impressive financial turnaround
The Canadian company reported a net income of C$4.8million for the quarter. This is a significant turnaround compared to the C$20.2million loss recorded during the same period in last year.
This performance was boosted by a 16 percent increase in revenue from plant propagation, which reached C$23.1 millions ($16.84million).
Aurora’s total revenue increased to C$83.4 Million, exceeding analysts’ expectations of C$77.6 Million and the C$74.7 Million reported in the prior year.
Medical cannabis: the driving force
Aurora’s medical marijuana segment saw a strong 13.5% increase in revenues, reaching C$47.2 millions.
This growth was offset by a 10% drop in consumer cannabis revenues, which fell to C$11.5million.
The strength of the medical cannabis sector has also contributed to a 87% increase in adjusted EBITDA which rose to C$4.9million.
CEO Miguel Martin expressed his confidence in the ability of the company to build on its successes in key markets like Germany, Australia, the UK, and others.
Martin emphasized Aurora’s commitments to operational excellence and growth strategy, with the aim of maintaining positive momentum and enhancing its market position.
Positive free cash flow, fiscal discipline and positive free cash flow
Aurora Cannabis reported a positive cash flow of $6,5 million for the third quarter.
The company attributed its success to the continued strength of medical cannabis, fiscal discipline and a strong balance sheet.
Martin stressed that these factors are critical to maintaining positive cash flow and supporting Aurora’s long-term strategy.
Aurora Cannabis’ stock is still down over 30% from its high for the year to date in late April, despite the positive earnings report.
The stock has risen over 100% in the last five months, indicating growing investor confidence in the turnaround efforts of the company.
Analyst says ‘hold’
Wall Street analysts give Aurora Cannabis a “hold” consensus rating, with a price target of approximately $6.34 a share.
This valuation is in line with the premarket trading price of the stock on Wednesday. This suggests that the current market may view the stock as fairly valued.
Is it too Late to Invest?
Investors are once again interested in Aurora Cannabis after the positive earnings report. The significant growth in medical cannabis has also boosted investor interest.
Investors should be aware that the stock currently does not pay a dividend. With its recent price increase, the market may view it as fully valued.
Before making an investment, it is prudent to carefully examine the future growth potential of the stock and market conditions.
Aurora Cannabis’ return of profitability and its strong performance in the medical marijuana sector mark a significant milestone.
Investors should be cautious and take into account the stock’s value and market dynamics when making investment decisions.
This post Aurora Cannabis reports profit with 87% EBITDA Growth, shares jump 11% – Is it too Late to Invest? This post may be updated as new information becomes available
This site is for entertainment only. Click here to read more
